Illumina told shareholders that Carl Icahn’s board nominees would “threaten the progress” of the biotech company’s core business.
Illumina told shareholders that Carl Icahn’s board nominees would “threaten the progress” of the biotech company’s core business.
){kind=link}
Comments
Comments are disabled for this post.